Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus

Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus

Type-2 diabetes mellitus (T2DM) patients who were on gliclazide co-administered with metformin were changed to pre-combined glibenclamide-metformin tablets in the Endocrine Clinic, Penang Hospital. We conducted a retrospective study to evaluate the differences in glycaemic control and treatment cost...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medical journal of Malaysia 2012-02, Vol.67 (1), p.21-24
Hauptverfasser: Lim, P C, Lim, S L, Oiyammaal, C
Format: Artikel
Sprache:eng
Schlagworte:
Blood Glucose - analysis
Costs and Cost Analysis
Diabetes Mellitus, Type 2 - drug therapy
Drug Therapy, Combination
Female
Gliclazide - administration & dosage
Glyburide - administration & dosage
Glycated Hemoglobin A - analysis
Humans
Hypoglycemic Agents - administration & dosage
Male
Metformin - administration & dosage
Middle Aged
Retrospective Studies
Tablets
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Type-2 diabetes mellitus (T2DM) patients who were on gliclazide co-administered with metformin were changed to pre-combined glibenclamide-metformin tablets in the Endocrine Clinic, Penang Hospital. We conducted a retrospective study to evaluate the differences in glycaemic control and treatment cost following the change. Eighty patients (60% females) with a mean age of 55 years old were studied. Mean glycosylated haemoglobin (HbAlc) reduction was -0.92% (p
ISSN:0300-5283